ARF6 Modulation of Chemokine Gradient Sensing Functions in Metastatic Cells

Information

  • Research Project
  • 8101672
  • ApplicationId
    8101672
  • Core Project Number
    R15GM097718
  • Full Project Number
    1R15GM097718-01
  • Serial Number
    097718
  • FOA Number
    PA-10-070
  • Sub Project Id
  • Project Start Date
    7/1/2012 - 12 years ago
  • Project End Date
    6/30/2016 - 8 years ago
  • Program Officer Name
    DEATHERAGE, JAMES F.
  • Budget Start Date
    7/1/2012 - 12 years ago
  • Budget End Date
    6/30/2016 - 8 years ago
  • Fiscal Year
    2012
  • Support Year
    01
  • Suffix
  • Award Notice Date
    6/15/2012 - 12 years ago

ARF6 Modulation of Chemokine Gradient Sensing Functions in Metastatic Cells

DESCRIPTION (provided by applicant): The normal function of the SDF-CXCR4 axis during development of the immune response, is to mediate migration of select hematopoietic, neuronal, and/or cardiovascular cells. The abnormal acquisition of functional CXCR4 receptors in several cancers, unmasks an ability of non-motile tumor cells to migrate and invade into SDF-expressing organs. These processes promote metastasis, the major cause of mortality in cancer patients. Therefore, developing strategies for CXCR4 inhibition are of great interest. In addition to the development of small molecule antagonists and neutralizing antibodies, vigorous attempts have been made to identify therapeutic targets that are required for CXCR4-mediated metastasis. We recently identified ARF6, a monomeric G protein of the Ras superfamily, as a novel regulator of CXCR4 trafficking and signaling. The proposed research specifically addresses an ARF6 requirement for CXCR4 functions which are dependent on SDF gradient sensing, including directional motility and differential signaling kinetics. This research will provide mechanistic insight into the acquisition of a metastatic phenotype, and will advance the establishment of ARF6 as a novel therapeutic target in aggressive CXCR4-expressing cancers. Aberrant CXCR4 expression was initially identified in breast carcinoma. However, CXCR4 has now been shown to be dysregulated in up to 23 different cancers including prostate carcinoma, melanoma, and neuroblastoma, greatly broadening the implications and future directions of the proposed research. Notably, breast and prostate carcinoma currently have the highest incidence and the second highest mortality rates. PUBLIC HEALTH RELEVANCE: The proposed research will significantly advance the establishment of a novel cancer therapeutic target, and provide mechanistic insight into the process of metastasis. Metastasis is the major cause of mortality in cancer patients. Therefore, this research will impact cancer-related health conditions.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R15
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
    227999
  • Indirect Cost Amount
    95271
  • Total Cost
    323270
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
    SCHOOLS OF PHARMACY
  • Funding ICs
    NIGMS:323270\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    MIST
  • Study Section Name
    Molecular and Integrative Signal Transduction Study Section
  • Organization Name
    UNIVERSITY OF THE SCIENCES PHILADELPHIA
  • Organization Department
    PHARMACOLOGY
  • Organization DUNS
    079497681
  • Organization City
    PHILADELPHIA
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    191044495
  • Organization District
    UNITED STATES